Recently Immunized Febrile Infants Have Low Infection Risk Recently Immunized Febrile Infants Have Low Infection Risk
Febrile infants showed a significantly reduced risk for serious bacterial infections within 24 hours after immunization but still had a persistent risk for urinary tract infections.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 15, 2024 Category: Consumer Health News Tags: Emergency Medicine Clinical Summary Source Type: news
D-Mannose as UTI Treatment Offers No Benefit D-Mannose as UTI Treatment Offers No Benefit
The dietary supplement D-mannose performed similarly to a placebo among women with recurrent urinary tract infections.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 11, 2024 Category: Consumer Health News Tags: Family Medicine/Primary Care Clinical Summary Source Type: news
D-Mannose Fails to Prevent Recurrent UTIs
(MedPage Today) -- D-mannose did not reduce the proportion of women with recurrent urinary tract infection (UTI), the randomized, placebo-controlled MERIT trial showed.
Over the 6-month study period, 51% of women taking 2-g D-mannose powder daily... (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - April 8, 2024 Category: OBGYN Source Type: news
How taking a probiotic pill to nurture your intimate area's microbiome may solve UTIs, itchy infections and other embarrassing symptoms
Picking up her sixth prescription of antibiotics for a urinary tract infection (UTI) in ten months, Kate Elgood was at her wit's end. (Source: the Mail online | Health)
Source: the Mail online | Health - April 8, 2024 Category: Consumer Health News Source Type: news
Vaccine-by-Mouth Could Replace Antibiotics in Fighting UTIs
MONDAY, April 8, 2024 -- A new oral vaccine could prove a potential alternative to antibiotics for people with recurring urinary tract infections, a new study says.More than half of patients with recurring UTIs (54%) wound up infection-free for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 8, 2024 Category: General Medicine Source Type: news
Recurrent UTI Patients Find Long-Term Ally in Oral Vaccine Recurrent UTI Patients Find Long-Term Ally in Oral Vaccine
A vaccine for urinary tract infection is effective for up to 9 years and can resolve cases in which antibiotics have failed.Medscape News UK (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - April 8, 2024 Category: Infectious Diseases Tags: Urology Source Type: news
Vaccine that can stop UTIs for NINE years - in drug that could prove a saviour for up to 1.7 million Britons
Research has found the treatment can prevent urinary tract infections (UTIs) for up to nine years in more than half of patients. The vaccine is given as a pineapple- flavoured oral spray. (Source: the Mail online | Health)
Source: the Mail online | Health - April 7, 2024 Category: Consumer Health News Source Type: news
The definitive expert guide to tackling UTIs: Ditch the bubble bath, avoid sweet treats, and the truth about cranberry juice
Britain is in the grip of an epidemic. It doesn't have the same fear factor as Covid-19. Yet urinary tract infections make life a misery for millions. But Dr Rajvinder Khasriya, pictured, can help. (Source: the Mail online | Health)
Source: the Mail online | Health - March 31, 2024 Category: Consumer Health News Source Type: news
New Insights Into the Persistent Pain of UTIs
MONDAY, March 4, 2024 -- People with recurring urinary tract infections frequently have persistent pain, even after antibiotics have cleared the harmful bacteria from their system.
Now, researchers have figured out why this perplexing problem... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 4, 2024 Category: General Medicine Source Type: news
Yogurt Can Now Claim It May Reduce the Risk of Diabetes
Yogurt sold in the U.S. can make claims that the food may reduce the risk of type 2 diabetes, based on limited evidence, the U.S. Food and Drug Administration said Friday.
The agency agreed that there is some evidence, but not significant scientific agreement, that eating at least 2 cups of yogurt per week may reduce the chance of developing the disease that affects about 36 million Americans.
FDA has allowed qualified health claims—a claim that lacks full scientific support but is allowed as long as there are disclaimers to keep from misleading consumers—for dietary supplements since 2000 and foods since...
Source: TIME: Health - March 2, 2024 Category: Consumer Health News Authors: JONEL ALECCIA/AP Tags: Uncategorized healthscienceclimate wire Source Type: news
FDA Approves Exblifep (cefepime/enmetazobactam) for the Treatment of Complicated Urinary Tract Infections
SAINT-LOUIS, France& WEILL AM RHEIN, Germany February 27, 2024 -- Allecra Therapeutics (“Allecra”), a biopharmaceutical company developing novel therapies to combat antibiotic resistance, announced today that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 27, 2024 Category: Drugs & Pharmacology Source Type: news
FDA Approves Antibiotic Combination for Complicated UTIs
(MedPage Today) -- The FDA approved the combination of cefepime and enmetazobactam (Exblifep) for the treatment of adult patients with complicated urinary tract infections, including pyelonephritis.
The agency's decision was based on data from... (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - February 24, 2024 Category: OBGYN Source Type: news
Venatorx expects FDA ruling on its potential flagship product this week after years in development
Venatorx Pharmaceuticals' potential flagship product, cefepime-taniborbactam, is an investigational combination antibiotic being developed to treat adults with complicated urinary tract infections. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 21, 2024 Category: Pharmaceuticals Authors: John George Source Type: news
Cefepime-Taniborbactam Superior to Meropenem for Complicated UTI
THURSDAY, Feb. 15, 2024 -- For adults with complicated urinary tract infection (UTI), including acute pyelonephritis, cefepime-taniborbactam is superior to meropenem, according to a study published in the Feb. 15 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 15, 2024 Category: Pharmaceuticals Source Type: news
Novel Antibiotic Combo Bests Meropenem for Complicated UTIs
(MedPage Today) -- Cefepime-taniborbactam, an investigational beta-lactam and beta-lactamase inhibitor combination, was superior to meropenem for the treatment of hospitalized patients with complicated urinary tract infection (UTI), including acute... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - February 15, 2024 Category: Infectious Diseases Source Type: news
